Skip to main content
Top
Published in: Trials 1/2020

Open Access 01-12-2020 | Irritable Bowel Syndrome | Study protocol

The efficacy of Bifidobacterium quadruple viable tablet in the treatment of diarrhea predominant irritable bowel syndrome: protocol for a randomized, double-blind, placebo-controlled, multicenter trial

Authors: Tao Bai, Haoyu Zeng, Yanqin Long, Xiaoqing Li, Xiaohong Sun, Yu Lan, Lingling Gao, Lu Zhang, Zenghui Feng, Xiaohua Hou

Published in: Trials | Issue 1/2020

Login to get access

Abstract

Background

Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders characterized by recurrent abdominal pain associated with defecation or a change in bowel habits. Leading to significant negative effect on patients’ quality of life and huge financial burden to health system, the management of IBS is a great challenge. Probiotics are considered as an effective therapy; however, in a lack of high-quality evidence of efficacy, no strain- and dose-specific probiotics were recommended in clinical guidelines. This study aims to evaluate the efficacy of the Bifidobacterium quadruple viable tablet in the treatment of IBS-D.

Methods/design

A multicenter randomized controlled trial will be performed in fourteen hospitals. A total of three hundred patients who fulfill the eligibility criteria will be stratified divided into an experimental group and a control group randomly in a ratio of 1:1. The experimental group is treated with the Bifidobacterium quadruple viable tablet while the control group is treated with placebo. All the patients will receive a 4-week treatment and a 2-week follow-up. The primary outcome is the effectiveness in improving abdominal pain and stool consistency; the secondary outcome includes evaluation of overall symptom relief, frequency of defecation, bloating, urgency of defecation, remedial medication, score of IBS-QOL, and changes of microbiota and metabonomics. Physical examination, vital signs, laboratory tests, adverse events, and concomitant medication will be taken into account for intervention safety assessment during the trial.

Discussion

This multicenter randomized controlled trial may provide high-quality evidence on the efficacy of the Bifidobacterium quadruple viable tablet for IBS-D on both physical and mental dimensions in China. To fill the gap of previous probiotic intervention studies, in addition, this study will also present safety assessment which will be a significant emphasis.

Trial registration

ChiCTR1800017721​. Registered on 10 August 2018.
Appendix
Available only for authorised users
Literature
1.
go back to reference Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorder. Gastroenterology. 2006;130(5):1480–91.CrossRef Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorder. Gastroenterology. 2006;130(5):1480–91.CrossRef
2.
go back to reference Mearin F, Lacy BE, Chang L, et al. Bowel disorders. Gastroenterology. 2016:S0016-5085(16)00222-5 [published online ahead of print, 2016 Feb 18]. Mearin F, Lacy BE, Chang L, et al. Bowel disorders. Gastroenterology. 2016:S0016-5085(16)00222-5 [published online ahead of print, 2016 Feb 18].
3.
go back to reference Sperber AD, Dumitrascu D, Fukudo S, Gerson C, Ghoshal UC, Gwee KA, Whitehead W. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. Gut. 2016;66(6):1075–82.CrossRef Sperber AD, Dumitrascu D, Fukudo S, Gerson C, Ghoshal UC, Gwee KA, Whitehead W. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. Gut. 2016;66(6):1075–82.CrossRef
4.
go back to reference Bai T, Xia J, Jiang Y, Cao H, Zhao Y, Zhang L, et al. Comparison of the Rome IV and Rome III criteria for IBS diagnosis: a cross-sectional survey. J Gastroenterol Hepatol. 2017;32(5):1018–25.CrossRef Bai T, Xia J, Jiang Y, Cao H, Zhao Y, Zhang L, et al. Comparison of the Rome IV and Rome III criteria for IBS diagnosis: a cross-sectional survey. J Gastroenterol Hepatol. 2017;32(5):1018–25.CrossRef
5.
go back to reference Wilkins T, Pepitone C, Alex B, Schade RR. Diagnosis and management of IBS in adults. Am Fam Physician. 2012;86:419–26.PubMed Wilkins T, Pepitone C, Alex B, Schade RR. Diagnosis and management of IBS in adults. Am Fam Physician. 2012;86:419–26.PubMed
6.
go back to reference Rivkin A, Rybalov S. Update on the management of diarrhea-predominant irritable bowel syndrome: focus on rifaximin and eluxadoline. Pharmacotherapy. 2016;36(3):300–16.CrossRef Rivkin A, Rybalov S. Update on the management of diarrhea-predominant irritable bowel syndrome: focus on rifaximin and eluxadoline. Pharmacotherapy. 2016;36(3):300–16.CrossRef
8.
go back to reference Bhattarai Y, Muniz Pedrogo DA, Kashyap PC. Irritable bowel syndrome: a gut microbiota-related disorder? Am J Physiol Gastrointest Liver Physiol. 2017;312(1):G52–62.CrossRef Bhattarai Y, Muniz Pedrogo DA, Kashyap PC. Irritable bowel syndrome: a gut microbiota-related disorder? Am J Physiol Gastrointest Liver Physiol. 2017;312(1):G52–62.CrossRef
9.
go back to reference Shanahan F, Quigley EMM. Manipulation of the microbiota for treatment of IBS and IBD—challenges and controversies. Gastroenterology. 2014;146(6):1554–63.CrossRef Shanahan F, Quigley EMM. Manipulation of the microbiota for treatment of IBS and IBD—challenges and controversies. Gastroenterology. 2014;146(6):1554–63.CrossRef
10.
go back to reference Harris LA, Baffy N. Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome. Postgrad Med. 2017;129(8):872–88.CrossRef Harris LA, Baffy N. Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome. Postgrad Med. 2017;129(8):872–88.CrossRef
11.
go back to reference Zhuang X, Xiong L, Li L, Li M, Chen M. Alterations of gut microbiota in patients with irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2017;32(1):28–38.CrossRef Zhuang X, Xiong L, Li L, Li M, Chen M. Alterations of gut microbiota in patients with irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2017;32(1):28–38.CrossRef
13.
go back to reference McKenzie YA, Thompson J, Gulia P, Lomer MCE. British Dietetic Association systematic review of systematic reviews and evidence-based practice guidelines for the use of probiotics in the management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet. 2016;29:576–92.CrossRef McKenzie YA, Thompson J, Gulia P, Lomer MCE. British Dietetic Association systematic review of systematic reviews and evidence-based practice guidelines for the use of probiotics in the management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet. 2016;29:576–92.CrossRef
14.
go back to reference Wilkins T, Sequoia J. Probiotics for gastrointestinal conditions: a summary of the evidence. Am Fam Physician. 2017;96(3):170–8.PubMed Wilkins T, Sequoia J. Probiotics for gastrointestinal conditions: a summary of the evidence. Am Fam Physician. 2017;96(3):170–8.PubMed
15.
go back to reference Yuan F, Ni H, Asche CV, Kim M, Walayat S, Ren J. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. Curr Med Res Opin. 2017;33(7):1191–7.CrossRef Yuan F, Ni H, Asche CV, Kim M, Walayat S, Ren J. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. Curr Med Res Opin. 2017;33(7):1191–7.CrossRef
16.
go back to reference Lan R, Koo J, Kim I. Effects of Lactobacillus acidophilus supplementation on growth performance, nutrient digestibility, fecal microbial and noxious gas emission in weaning pigs. J Sci Food Agric. 2016;97(4):1310–5.CrossRef Lan R, Koo J, Kim I. Effects of Lactobacillus acidophilus supplementation on growth performance, nutrient digestibility, fecal microbial and noxious gas emission in weaning pigs. J Sci Food Agric. 2016;97(4):1310–5.CrossRef
17.
go back to reference Wang S, Li H, Du C, Liu Q, Yang D, Chen L, Zhu Q, Wang Z. Effects of dietary supplementation with Lactobacillus acidophilus on the performance, intestinal physical barrier function, and the expression of NOD-like receptors in weaned piglets. PeerJ. 2018;6:e6060.CrossRef Wang S, Li H, Du C, Liu Q, Yang D, Chen L, Zhu Q, Wang Z. Effects of dietary supplementation with Lactobacillus acidophilus on the performance, intestinal physical barrier function, and the expression of NOD-like receptors in weaned piglets. PeerJ. 2018;6:e6060.CrossRef
18.
go back to reference Liu C, Zhu Q, Chang J, Yin Q, Song A, Li Z, et al. Effects of Lactobacillus casei and Enterococcus faecalis on growth performance, immune function and gut microbiota of suckling piglets. Arch Anim Nutr. 2017;71(2):120–33.CrossRef Liu C, Zhu Q, Chang J, Yin Q, Song A, Li Z, et al. Effects of Lactobacillus casei and Enterococcus faecalis on growth performance, immune function and gut microbiota of suckling piglets. Arch Anim Nutr. 2017;71(2):120–33.CrossRef
19.
go back to reference Samli HE, Dezcan S, Koc F, Ozduven ML, Okur AA, Senkoylu N. Effects of Enterococcus faecium supplementation and floor type on performance, morphology of erythrocytes and intestinal microbiota in broiler chickens. Br Poult Sci. 2010;51(4):564–8.CrossRef Samli HE, Dezcan S, Koc F, Ozduven ML, Okur AA, Senkoylu N. Effects of Enterococcus faecium supplementation and floor type on performance, morphology of erythrocytes and intestinal microbiota in broiler chickens. Br Poult Sci. 2010;51(4):564–8.CrossRef
21.
go back to reference Bottone EJ. Bacillus cereus, a volatile human pathogen. Clin Microbiol Rev. 2010;23(2):382–98.CrossRef Bottone EJ. Bacillus cereus, a volatile human pathogen. Clin Microbiol Rev. 2010;23(2):382–98.CrossRef
23.
go back to reference Zhang Y, Li L, Guo C, Mu D, Feng B, Zuo X, Li Y. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol. 2016;16(1):62.CrossRef Zhang Y, Li L, Guo C, Mu D, Feng B, Zuo X, Li Y. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol. 2016;16(1):62.CrossRef
24.
go back to reference Didari T. Effectiveness of probiotics in irritable bowel syndrome: updated systematic review with meta-analysis. World J Gastroenterol. 2015;21(10):3072.CrossRef Didari T. Effectiveness of probiotics in irritable bowel syndrome: updated systematic review with meta-analysis. World J Gastroenterol. 2015;21(10):3072.CrossRef
25.
go back to reference Camilleri M. Management options for irritable bowel syndrome. Mayo Clinic Proc. 2018;93(12):1858–72.CrossRef Camilleri M. Management options for irritable bowel syndrome. Mayo Clinic Proc. 2018;93(12):1858–72.CrossRef
26.
go back to reference Barbara G, Cremon C, Azpiroz F. Probiotics in irritable bowel syndrome: where are we? Neurogastroenterol Motil. 2018;30(12):e13513.CrossRef Barbara G, Cremon C, Azpiroz F. Probiotics in irritable bowel syndrome: where are we? Neurogastroenterol Motil. 2018;30(12):e13513.CrossRef
27.
go back to reference Hungin APS, Mulligan C, Pot B, Whorwell P, Agréus L, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide. Aliment Pharmacol Ther. 2013;38(8):864–86.CrossRef Hungin APS, Mulligan C, Pot B, Whorwell P, Agréus L, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide. Aliment Pharmacol Ther. 2013;38(8):864–86.CrossRef
28.
go back to reference Rondanelli M, Faliva MA, Perna S, Giacosa A, Peroni G, Castellazzi AM. Using probiotics in clinical practice: where are we now? A review of existing meta-analyses. Gut Microbes. 2017;8(6):521–43.CrossRef Rondanelli M, Faliva MA, Perna S, Giacosa A, Peroni G, Castellazzi AM. Using probiotics in clinical practice: where are we now? A review of existing meta-analyses. Gut Microbes. 2017;8(6):521–43.CrossRef
29.
go back to reference Mazurak N, Broelz E, Storr M, Enck P. Probiotic therapy of the irritable bowel syndrome: why is the evidence still poor and what can be done about it? J Neurogastroenterol Motil. 2015;21(4):471–85.CrossRef Mazurak N, Broelz E, Storr M, Enck P. Probiotic therapy of the irritable bowel syndrome: why is the evidence still poor and what can be done about it? J Neurogastroenterol Motil. 2015;21(4):471–85.CrossRef
30.
go back to reference McFarland LV, Evans CT, Goldstein EJC. Strain-specificity and disease-specificity of probiotic efficacy: a systematic review and meta-analysis. Front Med. 2018;5:124.CrossRef McFarland LV, Evans CT, Goldstein EJC. Strain-specificity and disease-specificity of probiotic efficacy: a systematic review and meta-analysis. Front Med. 2018;5:124.CrossRef
31.
go back to reference Doron S, Snydman DR. Risk and safety of probiotics. Clin Infect Dis. 2015;60(suppl_2):S129–34.CrossRef Doron S, Snydman DR. Risk and safety of probiotics. Clin Infect Dis. 2015;60(suppl_2):S129–34.CrossRef
33.
go back to reference WMA, World Medical Association. Declaration of Helsinki. J Am Med Assoc. 2013;227:925–6. WMA, World Medical Association. Declaration of Helsinki. J Am Med Assoc. 2013;227:925–6.
Metadata
Title
The efficacy of Bifidobacterium quadruple viable tablet in the treatment of diarrhea predominant irritable bowel syndrome: protocol for a randomized, double-blind, placebo-controlled, multicenter trial
Authors
Tao Bai
Haoyu Zeng
Yanqin Long
Xiaoqing Li
Xiaohong Sun
Yu Lan
Lingling Gao
Lu Zhang
Zenghui Feng
Xiaohua Hou
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Trials / Issue 1/2020
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-020-04490-0

Other articles of this Issue 1/2020

Trials 1/2020 Go to the issue